Market OpportunityThe market for RAS/RAF-wildtype CRC is large, with an annual total addressable market of around $12 billion, which presents a significant opportunity.
Regulatory ProgressThe company is confident in the regulatory path for petosemtamab in head and neck squamous cell carcinoma, with phase 3 trials showing promising results in both HPV+ and HPV- patients.
Stock Price PotentialThe price objective for Merus NV stock is set at 92.00 USD, indicating significant potential upside from the current price.